Structurally Mapping Antibody Repertoires

Konrad Krawczyk1, Sebastian Kelm2, Aleksandr Kovaltsuk1, Jacob D. Galson3, Dominic Kelly3, Johannes Trück3,4, Cristian Regep1, Jinwoo Leem1, Wing K. Wong1, Jaroslaw Nowak1, James Snowden2, Michael Wright2, Laura Starkie2, Anthony Scott-Tucker2, Jiye Shi2 and Charlotte M. Deane1*

1Department of Statistics, Oxford University, Oxford, United Kingdom, 2UCB Pharma, Slough, United Kingdom, 3Division of Immunology, Children’s Research Center, University Children’s Hospital, Zurich, Switzerland, 4Oxford Vaccine Group, University of Oxford, NHRI Oxford Biomedical Research Centre, Oxford, United Kingdom

Every human possesses millions of distinct antibodies. It is now possible to analyze this diversity via next-generation sequencing of immunoglobulin genes (Ig-seq). This technique produces large volume sequence snapshots of B-cell receptors that are indicative of the antibody repertoire. In this paper, we enrich these large-scale sequence datasets with structural information. Enriching a sequence with its structural data allows better approximation of many vital features, such as its binding site and specificity. Here, we describe the structural annotation of antibodies pipeline that maps the outputs of large Ig-seq experiments to known antibody structures. We demonstrate the viability of our protocol on five separate Ig-seq datasets covering ca. 35 m unique amino acid sequences from ca. 600 individuals. Despite the great theoretical diversity of antibodies, we find that the majority of sequences coming from such studies can be reliably mapped to an existing structure.

Keywords: antibody specificity, B-cell receptor, next-generation sequencing, structural homology, protein, bioinformatics tools

INTRODUCTION

Antibodies are proteins that play a key role in recognizing potentially noxious molecules (antigens) in jawed vertebrates. They are produced by B-cells, where they can be secreted or act as a membrane-bound B-cell receptor. In humans, they are composed of two polypeptide chains, referred to as heavy and light. Each of the chains has a variable region that is ca. 110 amino acids long, composed of the framework region and three hypervariable loops referred to as complementarity determining regions (CDRs). There is a limited set of known human germline framework sequences (~150), but CDRs, which dictate antigen recognition, show more variation (1). It is estimated that a typical human is capable of producing more than 10^10 distinct antibody molecules (2–6). Thus, in a single individual, there is likely to exist an antibody capable of recognizing an arbitrary antigen, though perhaps not specifically. Such binding malleability of antibodies has long been a subject of intensive academic and industrial research.

Discerning human antibody diversity will help us to understand how our immune system is capable of recognizing such a myriad set of antigens and underpins our ability to exploit them therapeutically (7–10). Next-generation sequencing of immunoglobulin genes (Ig-seq) facilitates this task as it allows us to obtain a snapshot of the B-cell receptor (antibody) repertoire across different individuals and immune states (11–16). The outputs from these Ig-seq experiments have been characterized by their germline biases and sequence analysis methods (2, 10, 14, 17, 18). These studies
do not consider the three-dimensional structure of the antibody, but it is this structure that dictates antigen recognition (19, 20). In one study, the authors structurally characterized a small portion of their Ig-seq data (ca. 2,000 structural models from ca. 175,000 sequences) but they did not produce a structural annotation protocol (21). In this paper, we show it is possible to characterize structurally large percentages of the data and describe a pipeline for automating the task.

As described by Kovalskuy et al. (20), structural information can give both an overall predicted shape and detail of the binding site (CDRs). Predicting the shape of a sequence can offer sufficient information to link it to an antibody with similar shape and defined antigen specificity (22, 23). Enriching Ig-seq datasets with structural information should improve analyses and insights that can be derived from antibody repertoire snapshots.

Here, we describe the structural annotation of antibodies (SAAB) algorithm to bridge the sequence-structure gap in antibody repertoire analysis. This protocol, given a FASTA file with potentially millions of antibody sequences, maps the full sequences, frameworks, and CDRs to the high quality antibody structures currently available in the Protein Data Bank (PDB) (24, 25). We demonstrate the validity of this approach by testing the protocol on five separate Ig-seq datasets encompassing ca 35 m sequences from ca. 600 individuals. For each dataset, we can associate a majority of frameworks and CDR sequences to an existing antibody structure. This finding recapitulates on a large scale both the structural conservation of the framework and the canonical CDR paradigm (26, 27). More generally, however, we demonstrate that it is currently possible to approximate the structures of entire variable region sequences for most of the data. Therefore, despite the theoretically allowed repertoire diversity, currently observed antibody sequence space appears to employ only a conservative set of structural shapes.

**MATERIALS AND METHODS**

**Structural Annotation of Antibodies**

Our SAAB algorithm accepts amino acid sequences in FASTA-formatted input. The algorithm first Chothia-numbers the sequences (28) and then maps (if possible) the sequences to known antibody structures in the PDB (25). These structures are identified for entire variable region as well as for frameworks and CDRs separately. Details of the steps of the protocol are given below.

**Chothia-Number Sequences**

Each of the supplied Ig-seq amino acid sequences are Chothia-numbered (28) using ANARCI (29). The numbering provides a consistent frame of reference for antibody sequences. This allows for sequence identity calculation of the entire sequence as well as regions of the antibody separately (frameworks and CDRs).

**Antibody Structural Reference**

The set of antibody structures accompanying our software and used in this analysis was downloaded from the structural antibody database (SAbDab) on 31st October 2017 (25). Only X-ray structures with resolution better than 3.0 Å were used. VHH structures were excluded. If both heavy and light sequences were identical across two or more molecules, only the structure with the best resolution was retained. This procedure resulted in 2,100 antibody structures. Each of the antibody chains is Chothia-numbered using ANARCI. We used these numbered structures to calculate the expected structural difference between two antibodies at a given sequence identity. We describe this structural difference using root mean square deviation (RMSD). RMSD estimates for values below 90% Chothia sequence identity were calculated using the subset of 711 non-redundant structures (less than 90% sequence identity) of the original 2,100 structures. The RMSD estimates above 90% sequence identity in Figure 2 were calculated using the entire set of 2,100 sequences. The RMSD calculation was done using TM-align (30).

**Chothia-Aligning Full Sequences and Frameworks**

Each amino acid sequence from an input Ig-seq dataset is Chothia-aligned to each of the 2,100 antibody structures. The sequence identity is normalized by the length of the query sequence. Chothia positions from the query sequence which cannot be found in the template are treated as mismatches. Sequence identity is calculated for the entire variable region and for the framework region separately. For framework alignments, we employ Chothia definitions of the CDR boundaries. Following this procedure, the PDB codes and chains of best full variable region and framework matches and the corresponding sequence identities are saved for each Ig-seq query sequence.

**CDR Annotations**

The original FREAD algorithm (31, 32) requires a database of fragments from which to select its predictions. In this case, for each CDR a separate database containing only CDRs of that type is used. FREAD also requires as minimal inputs the sequence of the loop to be modeled and the atomic coordinates of the two residues from the framework either side of the loop to be predicted (the anchor residues). Sequence identity of 50% or better between two antibody variable domains gives an anchor RMSD of around 0.4 Å or better. Thus, for a given CDR in a query sequence, we use the best full-sequence match to an existing antibody structure from step 2.1.3 as the anchor reference. From that point, the algorithm runs as described in the original papers [see Ref. (31, 32) for details] but with a length-dependent cutoff for the ESS score. This change was needed as FREAD had originally been benchmarked primarily on loops less than 13 residues long. For loop lengths below 13 the ESS cutoff is maintained at 25, between 13 and 16 the cutoff is set at 40, and for lengths greater than 16 the cutoff becomes 55. These thresholds were established by doing a one versus all cross-validation on a non-redundant set of antibodies in SAbDab at a 20% false positive rate (model has RMSD better than 1.5 Å with respect to the native structure). The anchor coordinates of the reference structure are used to perform a standard loop-template search for the query CDR sequence, using FREAD. If FREAD finds loops with closely matching anchors and an ESS score above the length-dependent cutoff, the best-scoring loop template’s PDB code and chain identifier are saved.
Output
For each query sequence, we output (if any) the PDB codes of the best full sequence matches, best framework matches, and best CDR matches. We also output the PDB codes that the largest number of query sequences were mapped to, allowing for large-scale structural characterization of the dataset. If an antibody structure (PDB code) has a bound antigen, these data are also retained to facilitate putative specificity annotation by rationale of sharing similar binding site.

Data
Four of the datasets (HBP, HBB, MEN, and FLU) were designed to study the immunization effects of vaccines targeting hepatitis B virus (primary and booster vaccination), meningococcus, and influenza virus, respectively. Nucleotide-deposited data for each of the datasets was downloaded from the NCBI website and translated to amino acid sequences. The original dataset sequences were separated by individuals, immunization visits (pre-vaccination or days post-vaccination), and isotype (IgG or IgM). For the purposes of this study, all the sequences from a given dataset were pooled together. These datasets are comprised exclusively of heavy chains. The UCB dataset was designed by UCB Pharma to be a comprehensive snapshot of baseline/naive human antibody diversity. This dataset consists of unpaired heavy and light IgM chains sourced from 494 individuals sampled from various immune organs. Sequences were not separated by individuals. Further details of generation of the datasets can be found in the Section Materials and Methods in Supplementary Material.

Availability
The SAAB protocol is available as a webserver which performs rapid structural mapping of individual sequences and indicates antigen targets of antibodies with similar binding sites. We also make the code available to perform bulk structural characterizations of large volumes of Ig-seq datasets locally. The amino acid sequences for datasets HBP, HBB, MEN, and FLU are freely available through our site. For the proprietary UCB_H and UCB_L datasets, a sequence-representative dataset, separate frameworks, and CDRs are made available. All the materials are available via http://antibodymap.org.

RESULTS
The SAAB Algorithm
The three-dimensional structures of antibodies define their binding properties and allow a more insightful analysis of these molecules (20). Currently, such structural information is missing from analyses of Ig-seq repertoires (20). In order to structurally enrich outputs of Ig-seq experiments, we have developed an algorithm for the SAAB, see Figure 1. The method is based on previously published ABodyBuilder and FREAD protocols that produce full models of the variable regions and protein loops, respectively (32, 33). These methods were validated by blind prediction of large structural datasets.

To demonstrate the efficacy of our protocol, we applied SAAB to five diverse Ig-seq datasets: one comprehensive dataset from ca. 500 people as well as four immunization datasets, each containing ~5 m unique amino acid sequences (Table 1).

The Majority of Full Variable Regions and Frameworks From Ig-seq Outputs Can be Reliably Matched to Available Structures
We quantified the proportion of sequences in each of our Ig-seq datasets for which it is possible to find a suitable structural
template. These closest structural matches tell us how well we can model each of the V-regions. Given the size of our Ig-seq datasets, the results indicate how well currently available

![Figure 2](https://www.frontiersin.org)

**Figure 2** | Chothia-aligning the 13.5 m unique baseline antibody variable sequences in datasets UCB_H and UCB_L to antibodies with known structures. (A) Full variable region sequence of the heavy chain. (B) Framework of the heavy chain. (C) Full variable region of the light chain. (D) Framework of the light chain. The pink bars indicate the number of sequences (right-hand y-axis) whose highest sequence identity structure match has the sequence identity given on the x-axis. The blue line (left-hand y-axis) indicates the expected root mean square deviation (RMSD) of a model built using a sequence identity match of that quality (with vertical SD error bars). For example, 80% sequence identity for the framework of the heavy chain translates to a 0.8 Å expected model RMSD.

| Dataset name | Non-redundant sequences | Individuals | Description |
|--------------|--------------------------|-------------|-------------|
| UCB_H        | H: 4,925,532             | 494 (pooled)| Proprietary, non-immunized comprehensive diversity library |
| UCB_L        | L: 8,380,540             |             |             |
| HBP          | H: 7,685,149             | 15          | Hep B Primary vaccination (34) |
| HBB          | H: 4,718,120             | 10          | Hep B Booster (12) |
| MEN          | H: 6,036,457             | 10          | Meningococcal vaccination (35) |
| FLU          | H: 3,409,916             | 58          | Influenza vaccination (36) |

We have employed one dataset of baseline antibody human diversity (UCB_L and UCB_H) and four immunized datasets (HBP, HBB, MEN, and FLU). In total, the datasets comprised ca. 600 individuals and ca. 36 m sequences.

The results of applying SAAB to the UCB_L and UCB_H datasets are shown in **Figure 2**. The blue lines indicate the RMSD that can be expected if a structural model was produced from a template with the sequence identity given on the x-axis [structures of 1.5 Å RMSD or better can be considered close to identical (1)]. The bars indicate the numbers of sequences in the Ig-seq dataset whose best structural template identified is of the corresponding sequence identity. These results suggest that there are few if any antibody framework structures unaccounted for as 97% of heavy chain and 94% of light chain frameworks in our dataset align to a PDB structure with over 80% sequence identity (thus expected model RMSD of 0.9 Å or better). The coverage is also similar for the entire variable region, suggesting that for the vast majority of sequences in the naïve human antibody repertoire sampled by datasets UCB_H and UCB_L we would be able to produce a structural model closely resembling the native structure. The blue line shows that even with
only 50% sequence identity an antibody framework would be predicted accurately. This shows the close structural homology of the framework sequences across V gene families (see Section 1 in Supplementary Material).

The other four datasets show a similar pattern (see Section 2 in Supplementary Material), which suggests that there are very few, if any “blind spots” in our knowledge of antibody domain structure. The antibody repertoire, as represented by the five datasets, appears to consist of a reasonably conservative set of scaffolds.

Therefore, using only 2,100 high quality antibody structures, it is possible to group Ig-seq space into general structural groups. Such broad-brush characterization can offer valuable information for structurally informed comparisons of sequences, but fails to address antibody specificity. In order to be able to draw conclusions about antibody specificity, it is necessary to map structurally the antibody binding site as defined by the CDRs.

Majority of CDR Sequences From Ig-seq Datasets Can Be Matched to an Existing Structural Template

We calculated the number of CDR sequences in our Ig-seq datasets for which we could find structural templates. The existence of a suitable structural template indicates that it is possible to produce a structural model of the loop. This, in turn, allows an approximation of the antibody binding site shape providing insight into its specificity.

For each Ig-seq dataset, we extracted the Chothia-defined CDR loops and grouped them by CDR type (H1, L2, etc.). Loops which were shorter than three amino acids long were discarded. We created redundant and non-redundant sets for each loop (see Table 2). We find that large proportions of the redundant non-H3 CDRs can be found directly in the PDB (Table 2). For instance, of the 4,718,716 H1 redundant loops in the UCB dataset, 2,238,760 (47%) are identical in sequence to a known H1 CDR antibody structure. By contrast, of the 110,495 non-redundant H1 loops in the UCB dataset, only 156 have identical sequence matches in the PDB. Non-H3 CDRs are known to adopt a limited number of canonical shapes so the high coverage of the redundant sequences is expected (27). The large discrepancy between the number of direct PDB matches between redundant and non-redundant datasets may indicate the existence of common loop sequences which thus have higher probability of having been crystallized at some point. We have listed all H1 and H2 loops for which we found a direct PDB match in Section 3 in Supplementary Material. These data show that these CDRs are shared between the five studies. Many of these CDRs are germline. To obtain a more comprehensive structural interpretation of the Ig-seq CDRs for which we do not find direct matches in the PDB, we predicted the loop conformation from sequence.

The structural templates for each CDR are identified using an adapted version of the loop-modeling algorithm FREAD (32) which was benchmarked for this particular study (see Materials and Methods). Given a query sequence, the algorithm determines if there is a fragment or loop in a pre-compiled structural database (in this case antibodies in the PDB) that would serve as a reliable modeling template (<1.5 Å RMSD). FREAD gives no prediction if it fails to find a close match. This allows us to produce an estimate for the percentage of CDR sequences we could reliably predict the structure of.

Using FREAD, we found that we could produce a reliable model for the majority of the CDR sequences in the UCB dataset (Table 2). Well over 50% of the unique sequences of non-H3 CDRs can be accurately structurally predicted. This appears to recapitulate on a large scale the canonical shape phenomenon of non-H3 CDRs. In the case of H3, even though there were only a handful of direct PDB matches to UCB_H H3 sequences, according to FREAD estimates, we would be able to produce structural models for 65% of all non-redundant and 75% of redundant H3 loops. This is a surprisingly high coverage given its theoretical sequence diversity and lack of canonical rules.

Similar results are seen for CDRs in the other four datasets (see Section 1 in Supplementary Material). Given the theoretically allowed diversity of antibody binding sites, these results suggest that the immune system is using only a limited set of CDR sequences and an even more limited set of CDR backbone shapes to generate diversity.

| Dataset and CDR subset | Total: redundant (non-redundant) | In the Protein Data Bank (PDB): redundant (non-redundant) | Can model: redundant (non-redundant) | Cannot model: redundant (non-redundant) |
|------------------------|---------------------------------|---------------------------------------------------------|-------------------------------------|----------------------------------------|
| UCB_H                  |                                 |                                                         |                                     |                                        |
| H1                     | 4,718,716 (110,495)              | 2,238,760 (159)                                         | 2,479,674 (110,245)                 | 282 (91)                              |
| H2                     | 4,718,717 (159,222)              | 1,568,190 (305)                                         | 3,150,527 (158,917)                 | 0 (0)                                 |
| H3                     | 4,714,545 (1,623,070)            | 61 (25)                                                 | 3,614,289 (1,088,900)               | 1,100,195 (534,145)                   |
| UCB_L                  |                                 |                                                         |                                     |                                        |
| L1                     | 8,127,157 (1,020,446)            | 889,922 (135)                                           | 7,206,821 (1,005,664)               | 30,414 (14,647)                       |
| L2                     | 8,127,157 (159,646)              | 2,942,147 (189)                                         | 5,137,392 (151,627)                 | 47,618 (7,830)                        |
| L3                     | 8,120,282 (1,080,668)            | 135,548 (130)                                           | 7,876,402 (1,060,293)               | 109,332 (20,245)                      |

Chothia-defined CDRs in each dataset were extracted from the full variable region. CDRs, which had length less than three, were discarded. The redundant datasets were constrained to unique sequences only, which we denote as “non-redundant,” and the resulting numbers of loops are given in the “Total” column. “In the PDB” indicates number of loops we could find direct sequences matches for in the PDB. Of the loops, which were not found directly in the PDB, the “Can model” column indicates the number of loops FREAD found suitable templates for. The “Cannot model” column shows the numbers of loops which were not in the PDB and FREAD could not find templates for. In each case, the numbers of redundant loops are given without parentheses whereas non-redundant loops are given in parentheses.
CONCLUSION

The diversity of the human antibody repertoire renders its characterization a challenging task. Newly available Ig-seq protocols allow us to take snapshots of this diversity across different individuals, isotypes, and immune states. Current Ig-seq analysis pipelines rely on sequence-only methods to gain insight into antibody mechanics. However, it is the three-dimensional structure of the antibody that defines the specific physicochemical configuration which modulates the molecule's specificity and affinity. Enriching Ig-seq datasets with structural information would greatly help in drawing biological or therapeutic conclusions about sequencing data (20).

In order to bridge the gap between high-throughput antibody sequencing and three-dimensional structure we developed SAAB. Our algorithm identifies the most suitable (if any) structural templates for the entire variable region as well as the framework and CDR regions alone. We tested the method on five datasets containing over 36 m sequences and show that the 2,100 high quality antibody structures in the public domain are sufficient to structurally annotate the majority of sequences.

The ability to identify structural templates for the majority of frameworks is expected since these are drawn from a limited set of known germlines. Similarly, non-H3 CDRs are known to adopt a set of canonical shapes. Furthermore, there appears to be a large proportion of non-H3 CDR shapes that are highly re-used in the datasets. Considering the diversity and volume of the datasets involved it may be the case that the majority of the human immune repertoire is composed of a limited, perhaps strategically preferred, set of sequences and an even more conservative set of backbone shapes.

Binding shape biases in antibody repertoires can offer insight into the strategies of the immune system for tackling arbitrary antigens. For instance, sequence similarities can be indicative of shared antigen specificity (16, 37). However, the particular three-dimensional configuration of the CDRs can help in identifying the physicochemical properties of the paratope, providing potentially clearer information on specificity (21). It was previously shown on a smaller scale that certain CDR length or canonical class combinations can be associated with different types of antigens (38, 39). Thus, sharing of a similar structural template could also be an indication of similar specificity (Figure 3). However, this is only the first step in identifying potential antigen-specific antibodies within the totality of the repertoire. Such candidates would have to be carefully studied with respect to the physicochemical properties of their paratopes, as such non-covalent interactions are known to ultimately dictate antibody-antigen recognition (39, 40). Special focus should be placed on electrostatic interactions that are suggested to be of particular importance in antibody–antigen complexes (41, 42). Annotating sequences with such physicochemical information can only be done reliably given the structure of the antibody (43). Such structural annotations will become more pertinent and accurate as more paired Ig-seq datasets are released as these data allow the entire Fv to be modeled rather than separate heavy and light chains (21). Such disease-specific annotations could be employed in immunodiagnostics to find antibody-markers of known diseases. Therefore, employing structural information provides novel ways to study the diversity of the immune system.

Up until now, structural mapping of entire repertoires was hampered by the computational cost associated with variable region modeling. Nevertheless, just identifying templates without producing a detailed model is in most cases more feasible than producing an ideal structural model and is already representative of shape (1, 21). For instance, rapidly identifying structurally similar groups by shared templates or structural similarity among templates in immunized Ig-seq datasets could be indicative of antigenic specificity. Employing structural annotations in such a fashion could allow for the development of computationally rapid predictive methodology for selecting antibody sequences to experimentally test for binding to an antigen. The inability to better identify antigen-specific sequences from sequence alone has been long proposed as a roadblock to better vaccine development (16).

Furthermore, it has been shown previously that certain antigen-specific sequences can be found across different individuals (44, 45). Such antibodies were proposed to constitute the so-called “public repertoire” indicating sequence convergences within the population to combat certain groups of antigens (45, 46). SAAB annotations will offer an opportunity for in-depth characterization of structural commonalities and divergences in the inter-individual repertoires (46). For instance, comparing the overlap of subsets of structural annotations between individuals of healthy and diseased states could shed light on preferred groups of antibodies used for antigen recognition. The large sequence redundancy we observe here offers further evidence that there are antibodies that might be preferentially used by an organism to carry out immune responses. The high level of structural coverage we observe here
suggested that repertoires in general and the public repertoire in particular is structurally conservative, perhaps indicating immune preferences beyond germline genes. Therefore, characterization of antibody repertoires in terms of sequence and structural features will help us to understand the strategic choices made by organisms which can, in turn, improve our ability for therapeutic design of these molecules. SAAB allows researchers to enrich Ig-seq datasets with structural information empowering them to draw greater biologically and therapeutically relevant information from their data.

**AUTHOR CONTRIBUTIONS**

KK, SK, JaS, MW, JiS, and CD conceived the experiments. JaS, in particular is structurally conservative, perhaps indicating information from their data.

**REFERENCES**

1. Almagro JC, Teplyakov A, Luo J, Sweet RW, Kodangattil S, Hernandez-Guzman F, et al. Second antibody modeling assessment (AMA-II). *Proteins* (2014) 82:1533–62. doi:10.1002/prot.24567
2. Glinville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. *Proc Natl Acad Sci U S A* (2009) 106:20216–21. doi:10.1073/pnas.0909775106
3. Fanning LJ, Connor AM, Wu GE. Development of the immunoglobulin repertoire. *Clin Immunol Immunopathol* (1996) 79:1–14. doi:10.1006/clim.1996.0044
4. Perelson AS, Oster GF. Theoretical studies of clonal selection: minimal antibody repertoire size and reliability of self-non-self discrimination. *J Theor Biol* (1979) 81:645–70. doi:10.1016/0022-5193(79)90275-3
5. Tonegawa S. Somatic generation of antibody diversity. *Nature* (1983) 302:575–81. doi:10.1038/302575a0
6. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. *Molecular Biology of the Cell*. 4th ed. New York: Garland Science (2002).
7. Murad JP, Lin OA, Espinosa EVP, Khasawneh FT. Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions. *Curr Mol Med* (2013) 13:165–78. doi:10.2174/156652413804486322
8. Presta LG. Molecular engineering and design of therapeutic antibodies. *Curr Opin Immunol* (2008) 20:460–70. doi:10.1016/j.coi.2008.06.012
9. Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. *Curr Opin Pharmacol* (2012) 12:615–22. doi:10.1016/j.coph.2012.08.001
10. Hoehn KB, Fowler A, Lunter G, Pybus OG. The diversity and molecular evolution of B cell receptors during infection. *Mol Biol Evol* (2016) 33(5): 1147–57. doi:10.1093/molbev/msw015
11. Georgiou G, Ippolito GC, Beausang J, Basse CE, Wardemann H, Quake SR. The promise and challenge of high-throughput sequencing of the antibody repertoire. *Nat Biotechnol* (2014) 32:158–68. doi:10.1038/nbt.2782
12. Galson J, Trücks J, Fowler A, Catterbuck EA, Münn M, Cerundolo V, et al. Analysis of B cell repertoire dynamics following hepatitis B vaccination in humans, and enrichment of vaccine-specific antibody sequences. *EBioMedicine* (2015) 2:2070–9. doi:10.1016/j.ebiom.2015.11.034
13. Kaplinsky J, Li A, Sun A, Coffre M, Korolav SB, Arnaout R. Antibody repertoire deep sequencing reveals antigen-independent selection in maturing B cells. *Proc Natl Acad Sci U S A* (2014) 111:E2622–9. doi:10.1073/pnas.1403278111
14. Dekosky BJ, Kojima T, Rodin A, Charab W, Ippolito GC, Ellington AD, et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. *Nat Med* (2015) 21:86–91. doi:10.1038/nm.3743
15. Boyd SD, Marshall EL, Merker JD, Maniari JM, Zhang LN, Sahaf B, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel V-D-J pyrosequencing. *Sci Transl Med* (2009) 1:ra23–12. doi:10.1126/scitranslmed.3000540
16. Trücks J, Ramasamy MN, Galson JD, Rance R, Parkhill J, Lanter G, et al. Identification of antigen-specific B cell receptor sequences using public repertoire analysis. *J Immunol* (2015) 194:252–61. doi:10.4049/jimmunol.1401405
17. Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, Weiland M, et al. High-resolution description of antibody heavy-chain repertoire in humans. *PLoS One* (2011) 6(8):e22365. doi:10.1371/journal.pone.0022365
18. Glinville J, Kuo TC, von Büdingen H-C, Guey L, Berka J, Sundar PD, et al. Naïve antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. *Proc Natl Acad Sci U S A* (2011) 108:20066–71. doi:10.1073/pnas.1107498108
19. Peng H-P, Lee KH, Jian J-W, Yang A-S. Origins of specificity and affinity in antibody-protein interactions. *Proc Natl Acad Sci U S A* (2014) 111:E266–65. doi:10.1073/pnas.1401131111
20. Kovaltsuk A, Krawczyk K, Galson JD, Kelly DF, Deane CM, Trücks J. How B-cell receptor repertoire sequencing can be enriched with structural antibody data. *Front Immunol* (2017) 8:1753. doi:10.3389/fimmu.2017.01753
21. DeKosky BJ, Lungu OI, Park D, Johnson EL, Charab W, Chrysostomou C, et al. Large-scale sequence and structural comparisons of human naïve and antigen-experienced antibody repertoires. *Proc Natl Acad Sci U S A* (2016) 113(19):E2636–45. doi:10.1073/pnas.1525510113
22. Ponomarenko J, Papangeliopoulos N, Zajonc DM, Peters B, Sette A, Bourne PE. IEDB-3D: structural data within the immune epitope database. *Nucleic Acids Res* (2011) 39:D1164–70. doi:10.1093/nar/gkq888
23. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, et al. Immune epitope database analysis resource. *Nucleic Acids Res* (2012) 40(Web Server issue):W525–30. doi:10.1093/nar/gks438
24. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. *Nucleic Acids Res* (2000) 28:235–42. doi:10.1093/nar/28.1.235
25. Dunbar J, Krawczyk K, Leem J, Baker T, Fuchs A, Georges G, et al. SABDab: the structural antibody database. *Nucleic Acids Res* (2015) 43:1140–6. doi:10.1093/nar/gkt1043
26. Nowak J, Baker T, Georges G, Kelm S, Klostermann S, Shi J, et al. Length-independent structural similarities enrich the antibody CDR canonical class model. *Mabs* (2016) 8:751–60. doi:10.1080/19420862.2016.1158370
27. Chotia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. *J Mol Biol* (1987) 4:901–17. doi:10.1016/0022-8367(87)90412-8
28. Chotia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. *Nature* (1989) 342:877–83. doi:10.1038/342877a0
29. Dunbar J, Deane CM. ANARCI: antigen receptor numbering and receptor classification. *Bioinformatics* (2016) 32(2):298–300. doi:10.1093/bioinformatics/btv552
30. Zhang Y, Skolnick J. TM-align: a protein structure alignment algorithm based on the TM-score. *Nucleic Acids Res* (2005) 33:2302–9. doi:10.1093/nar/gki524
31. Deane CM, Blundell TL. CODA: a combined algorithm for predicting the structurally variable regions of protein models. *Protein Sci* (2001) 10:599–612. doi:10.1110/ps.37601
32. Choi Y, Deane CM. FREAD revisited: accurate loop structure prediction using a database search algorithm. *Proteins* (2010) 78:1431–40. doi:10.1002/prot.22658
33. Leem J, Dunbar J, Georges G, Shi J, Deane CM. ABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation. *MAbs* (2016) 8:1259–68. doi:10.1080/19420862.2016.1205773
34. Galson J, Trück J, Clutterbuck EA, Fowler A, Cerundolo V, Pollard AJ, et al. B cell repertoire dynamics after sequential hepatitis B vaccination, and evidence for cross-reactive B cell activation. *Genome Med* (2016) 8(1):68. doi:10.1186/s13073-016-0322-z
35. Galson J, Clutterbuck EA, Trück J, Ramasamy MN, Münz M, Fowler A, et al. BCR repertoire sequencing: different patterns of B-cell activation after two meningococcal vaccines. *Immunol Cell Biol* (2015) 93:885–95. doi:10.1038/icb.2015.57
36. Galson J, Trück J, Kelly DF, van der Most R. Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination. *Sci Rep* (2016) 6:37229. doi:10.1038/srep37229
37. Parameswaran P, Liu Y, Roskin KM, Jackson KKL, Dixit VP, Lee JY, et al. Convergent antibody signatures in human dengue. *Cell Host Microbe* (2013) 13:691–700. doi:10.1016/j.chom.2013.05.008
38. Collis AVJ, Brouwer AP, Martin ACR. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. *J Mol Biol* (2003) 325:337–54. doi:10.1016/S0022-2836(02)01222-6
39. Lara-Ochoa F, Almagro JC, Vargas-Madrazo E, Conrad M. Antibody-antigen recognition: a canonical structure paradigm. *J Mol Evol* (1996) 43:678–84. doi:10.1007/BF02202116
40. Van Oss CJ. Hydrophobic, hydrophilic and other interactions in epitope-paratope binding. *Mol Immunol* (1995) 32:199–211. doi:10.1016/0161-5890(94)00124-J
41. Sinha N, Mohan S, Lipschultz CA, Smith-Gill SJ. Differences in electrostatic properties at antibody–antigen binding sites: implications for specificity and cross-reactivity. *Biophys J* (2002) 83:2946–68. doi:10.1016/S0006-3495(02)75302-2
42. Lippow SM, Wittrup KD, Tudor B. Computational design of antibody-affinity improvement beyond in vivo maturation. *Nat Biotechnol* (2007) 25:1171–6. doi:10.1038/nbt1336
43. Jubb HC, Higueroelo AP, Ochoa-Montaño B, Pitt WR, Ascher DB, Blundell TL. Arpeggio: a web server for calculating and visualising interatomic interactions in protein structures. *J Mol Biol* (2017) 429:365–71. doi:10.1016/j.jmb.2016.12.004
44. Galson J, Trück J, Fowler A, Münz M, Cerundolo V, Pollard AJ, et al. In-depth assessment of within-individual and inter-individual variation in the B cell receptor repertoire. *Front Immunol* (2015) 6:531. doi:10.3389/fimmu.2015.00531
45. Hoi KH, Ippolito GC. Intrinsic bias and public rearrangements in the human immunoglobulin Vλ light chain repertoire. *Genes Immun* (2013) 14(4):271–6. doi:10.1038/gene.2013.10
46. Greiff V, Weber CR, Palme J, Bodenhofer U, Miho E, Menzel U, et al. Learning the high-dimensional immunogenomic features that predict public and private antibody repertoires. *J Immunol* (2017) 199(8):2985–97. doi:10.4049/jimmunol.1700594

**Conflict of Interest Statement:** SK, JS, LS, MW, AS-T, and JS were employed by company UCB Pharma. All other authors declare no competing interests.

Copyright © 2018 Krawczyk, Kelm, Kovaltsuk, Galson, Kelly, Trück, Regep, Leem, Wong, Nowak, Snowden, Wright, Starkie-Tucker, Shi and Deane. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.